Jag Capital Management LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Jag Capital Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 121,427 shares of the biopharmaceutical company’s stock after purchasing an additional 9,326 shares during the quarter. Gilead Sciences comprises approximately 1.9% of Jag Capital Management LLC’s investment portfolio, making the stock its 20th biggest position. Jag Capital Management LLC’s holdings in Gilead Sciences were worth $16,923,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $26,000. Wealth Preservation Advisors LLC lifted its stake in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,000 shares of company stock valued at $9,978,740 in the last three months. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $136.30 on Friday. The company has a market capitalization of $169.23 billion, a price-to-earnings ratio of 18.57 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a 50 day moving average price of $129.67 and a 200 day moving average price of $135.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period last year, the business earned $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Leerink Partners decreased their target price on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Citigroup upped their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Monday, July 6th. Royal Bank Of Canada dropped their price target on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Finally, Truist Financial reduced their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $159.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.